Critical Development Needs for Recombinant Blood-Coagulation Factors

O. B. Ustinnikova; O. B. Runova; E. V. Novikova; V. P. Bondarev; E. V. Lebedinskaya

doi:10.1007/s11094-016-1492-0

Critical Development Needs for Recombinant Blood-Coagulation Factors

Autores: Ustinnikova O.B.¹, Runova O.B.¹, Novikova E.V.¹, Bondarev V.P.¹, Lebedinskaya E.V.¹
Afiliações:
1. State Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
Edição: Volume 50, Nº 9 (2016)
Páginas: 573-576
Seção: Molecular-Biological Problems of Drug Design and Mechanism of Drug Action
URL: https://ogarev-online.ru/0091-150X/article/view/244439
DOI: https://doi.org/10.1007/s11094-016-1492-0
ID: 244439

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

Critical development needs for recombinant blood-coagulation factors (RBCFs) are reviewed. The production of less immunogenic drugs with suppressed induction of inhibitory antibodies and prolonged therapeutic effects resulting from an increased inactivation threshold is demonstrated to be a major need for designing new RBCF modifications differing in structure and composition from endogenous blood-coagulation factors while retaining their activity.